Table 1.

Bacterial strainsa

IsolateDescriptionMIC (μg/ml)SourceReference
VmbTcob
MIClass A GISA clinical isolatec 68CDC isolate HIP5827 (Fred Tenover) 4, 5,21
MI (P60)MI passaged on BHI for 60 days23 2
NJClass B GISA clinical isolate55CDC isolate HIP5836 (Fred Tenover) 5, 21
NJ (P15)NJ passaged on BHI for 15 days34 2
PCClass B GISA clinical isolate55CDC isolate HIP 6297 (Fred Tenover) 18, 19
PC (P15)PC passaged on BHI for 15 days23 2
Mu50Class B GISA isolate55K. Hiramatsu (Tokyo, Japan) 10,12, 13
Mu50 (P15)Mu50 passaged on BHI for 15 days22 2
Mu3Class C GISA clinical isolate29K. Hiramatsu 10, 12,13
Mu3 (P15)Mu3 passaged on BHI for 15 days26 2
BB589 femCmutant1d 2d B. Berger-Bachi (Zurich, Switzerland) 22
H1MRSA isolate from a Japanese patient with pneumonia believed to have responded favorably to vancomycin2e, 3/4-5d 8e, 6-12/12d K. Hiramatsu 12
IL (isolate X31325)MRSA isolate14R. Carey (Maywood, Ill.) 3
IL (isolate T78628)GISA isolate8NDR. Carey 3
  • a Abbreviations: CDC, Centers for Disease Control and Prevention (Atlanta, Ga.); classes A, B, and C, glycopeptide resistance (class A, vancomycin intermediate, teicoplanin intermediate; class B, vancomycin intermediate, teicoplanin susceptible; class C, vancomycin susceptible, teicoplanin intermediate); BHI, brain heart infusion broth; Vm, vancomycin; Tco, teicoplainin; ND, not determined.

  • b Values were published previously (2), except for those for isolates BB589 (femCmutant), H1, IL (isolate X31325), and IL (isolate T78628).

  • c The MIC of teicoplanin for this isolate was determined to be 16 μg/ml by investigations performed at the Centers for Disease Control and Prevention. This value justified the class A designation. At the University of Chicago, a value of 8 μg/ml has been consistently obtained. This value would render the isolate class B.

  • d Done at the University of Chicago in brain heart infusion broth at 24 h/48 h.

  • e Done at the University of Chicago in Mueller-Hinton broth at 24 h.